

sen-Jam  
PHARMACEUTICAL

**PROTECTING  
HEALTHSPAN BY  
REVOLUTIONIZING  
INFLAMMATORY CARE**



# DISCLOSURE STATEMENT

This presentation was prepared by Sen-Jam Pharmaceutical, Inc. (the “Company”) exclusively for the benefit and internal use of the party to whom it is provided to by the Company and is the confidential information of the Company. Any further distribution or reproduction of this presentation, in whole or in part, or the divulgence of any of its contents, is unauthorized. This presentation is for discussion purposes only. No representation, express or implied, is being given by the Company as to the accuracy or completeness of the information contained herein.

This presentation contains “forward-looking” statements, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, should be deemed forward-looking statement, and reflect the Company's current expectations and assumptions about future events and are not guarantees of future performance. Actual results could differ materially from the Company's current expectations because of many factors. All forward-looking statements herein reflect opinions only as of the date of this presentation.

# INFLAMMATION IS SILENTLY KILLING US



## 3 OUT OF EVERY 5 DEATHS WORLDWIDE

are due to inflammatory diseases including heart disease, obesity, respiratory infections, etc.



## 150 MILLION AMERICANS

suffer from chronic inflammation.




## 1 IN 4 PEOPLE WORLDWIDE SUFFER FROM “META-FLAMMATION”

Obesity and Metabolic Disorders related to low-grade chronic inflammation.

Sources: [StatPearls](#), [Rand Corporation](#), [CDC](#)

### UNITED STATES LIFE EXPECTANCY



Over the last 4 years, Americans have  
**LOST 3 YEARS IN LIFE EXPECTANCY**



# TODAY'S ANTI-INFLAMMATORIES ARE FAILING US



**POOR  
EFFICACY**



**NEGATIVE SIDE  
EFFECTS**



**TOXIC**



**HIGH  
COSTS**




**ONLY ADDRESS  
SYMPTOMS**



**FAIL TO STOP  
DISEASE  
PROGRESSION**



# WHERE DOES INFLAMMATION COME FROM? ...AND MORE URGENTLY, WHERE DOES IT GO?



# PAIR TECHNOLOGY PLATFORM: A FIRST-IN-CLASS EFFECTIVE, COMPREHENSIVE PRECISION MEDICINE

## Pleiotropic Anti-Inflammatory Remedies

*Multi-action mechanism that reduces and resolves inflammation*

	Cytokine Inhibition	NF-κB Inhibition	TLR4 Inhibition	PG/LT Pathway	JAK/STAT Modulation	Resolution of Inflammation	Anti-Oxidant Action	Immuno-Suppression
SJP PAIR Technology								
Steroids								
Monoclonal Antibodies								
NSAIDs								
JAK/STAT Inhibitors								

Faster and more Complete Resolution of Inflammation with Protection Against Long-term Damage and Disease Progression. Making this a First Line Therapeutic to Preempt Inflammation Worldwide

# WE'RE THE BIGGEST ADVANCEMENT TACKLING INFLAMMATION IN 125 YEARS

**GAME-CHANGING  
ANTI-INFLAMMATORIES**



**DUAL-MOA THAT  
TREATS THE SOURCE**

- ❑ Orchestrates multiple pathways at once, not just one
- ❑ Powerful benefits + exceptional safety = true synergistic effects
- ❑ Stops inflammation at its source before it spirals out of control
- ❑ First therapy to resolve inflammation, not just suppress it

**Aspirin  
Invented by  
Hoffman**



**1897**

**Cortisone/  
Steroids invented  
by Hench & Kendall**




**1950**

**Indomethacin  
Enters the  
market**



**1960**

**Celebrex  
Introduced**




**1990**

**sen-jam**  
PHARMACEUTICAL

# THE POWERFUL ROLE OUR PLATFORM PLAYS IN HEALTHSPAN

Three types of inflammation: acute, chronic and low-grade chronic





# PAIR TECHNOLOGY PLATFORM IN “META-FLAMMATION”: A FIRST LINE AGENT TO SUPPORT METABOLIC BALANCE

Pleiotropic **Anti-Inflammatory Regulators**  
*Multi-action mechanism that reduces and resolves inflammation*

## Projected Endpoints


Endpoint	SJP-001 OTC	SJP-002C Rx	GLP-1 Receptor Agonist	Dual GIP/GLP-1 Receptor Agonist	Combination Therapy*
Weight Loss (% of BW)	2-4%	3–5%	10–15%	15–22.5%	20–25%
BMI Reduction	1-3%	5%	10–15%	18%	20–25%
HbA1c Reduction	0.25-0.5%	0.5–1.0%	1.5%	2.0%	2.3%
Liver Fat Reduction	15-20%	25-40%	30%	35%	45-50%
CRP Reduction	50-60%	55-65%	25%	37.5%	45%
HOMA-IR Improvement	15%	20%	30%	40%	45%

\*Adding SJP-002C to Incretin Mimetics

# MASTERING INFLAMMATION: THE KEY TO TREATING & DELAYING AGE-RELATED DISEASES

PAIR Technology is uniquely poised to revolutionize inflammatory care and bridge both longevity and disease management communities

SJP Pipeline





Jackie Iversen, RPh, MS  
Founder, Sen-Jam Pharmaceutical

**“PREVENTION IS THE  
NEW *WILDLY MASSIVE*  
UNMET NEED... AND IT  
MUST BE *SAFE AND*  
*ACCESSIBLE TO ALL*”**

*January 2019*



# REDEFINING THE FUTURE OF INFLAMMATORY CARE

*Setting a New Standard of Care*


**PREEMPTIVE SOLUTIONS THAT  
RESOLVE INFLAMMATION SAFELY,  
TO PREVENT DISEASE AND PROTECT  
HEALTHSPAN FOR ALL**

Ushering in the Next Era that  
goes *Beyond BioTech*

1. **INCLUSIVITY**
2. **LEGACY SAFETY**
3. **EARLY INTERVENTION**
4. **PRECISION MEDICINE  
WITHOUT COMPLEXITY**

# OUR PORTFOLIO OF 11 ASSETS IS PROTECTED BY 60+ PATENTS IN 23 COUNTRIES

## TARGETING 8 MASSIVE THERAPEUTIC AREAS:





## II SCIENTIFIC PAPERS PUBLISHED BY SJP IN PRESTIGIOUS JOURNALS

















PAIR TECHNOLOGY LEVERAGES TWO WELL CHARACTERIZED, SAFE MOLECULAR CATEGORIES IN UNIQUELY NOVEL COMBINATION FOR PRECISION TARGETING OF INFLAMMATION


RX OTC

We are de-risking the regulatory pathway for treating acute and chronic inflammatory TAs


			DISCOVERY	SCREENING	PRECLINICAL	PHASE I	PHASE 2	PHASE 3	CLINICAL TRIAL PARTNERSHIPS	
OBESITY			COVID-19/URI	SJP-002C SARS-CoV-2-Mild to Moderate Infection - Oral					OUT-LICENSING DILIGENCE	
				SJP-100 SARS-CoV-2-Severe Infection - Injectable						
		ADVERSE EFFECTS OF ALCOHOL	SJP-001 Alcohol Hangover Prevention - Oral					OUT-LICENSING DILIGENCE		
		OPIOID USE DISORDER	SJP-005 Opioid Withdrawal - Oral					RECENT NIDA PARTNERSHIP FOR POLY SUBSTANCE USE DISORDER		
			SJP-006 Opioid Dependence - Oral							
			SJP-007 Opioid Tolerance - Oral							
		VACCINATION SIDE-EFFECTS	SJP-003 Adverse Effects from Vaccine - Oral					RECENTLY GRANTED US PATENT		
		UPPER RESPIRATORY INFECTIONS	SJP-002 Viral Respiratory Infection - Oral							
		ARTHRITIS	SJP-004 Arthritis - Oral							
			SJP-101 Arthritis - Injectable							
		PREMATURE AGING	SJP-200 Low-grade Chronic Inflammation - Oral							

**SEN-JAM'S MISSION IS TO  
MAKE OUR REVOLUTIONARY  
ANTI-INFLAMMATORIES  
ACCESSIBLE TO ALL**

**CAPTURING  
A MASSIVE \$367B  
GLOBAL MARKET  
OPPORTUNITY**



# BY DE-RISKING AND ACQUIRING ROBUST IP PROTECTION, SEN-JAM UNIQUELY ACCELERATES COMMERCIAL VALUE



## LEAD ASSETS:

### SJP-001

Alcohol Hangover – 23 country patents granted / 1 pending

### SJP-002C

Upper Respiratory Infections (COVID, RSV, Influenza) – 15 country patents pending / Manf. process patent pending

### SJP-002

Upper Respiratory Infections (Common Cold) – 1 US patent granted

### SJP-005

Opioid Withdrawal – 3 country patents granted/5 pending



# LED BY BEST-IN-CLASS MEDICAL PROFESSIONALS & ENTREPRENEURIAL INNOVATORS WITH OVER **\$730M** IN EXITS

THE GOOD karma PHARMA PEOPLE



**JACKIE IVERSEN**  
RPh MS, Co-Founder,  
Chief Clinical Officer  
Visionary Pharmacist



**JIM IVERSEN**  
Co-Founder,  
CEO  
Business Transformer



**THOMAS DAHL**  
PhD,  
Head of Regulatory Affairs  
Regulatory Expert



**NEAL ZAHN**  
Director of  
Global Licensing  
Global Operator



**CHRISTINE LEONARD**  
Director of  
Communications  
Corporate Strategist



Memorial Sloan Kettering  
Cancer Center



**ALEXANDER WISSNER-GROSS**  
PhD,  
Advisor  
Futurist, Physicist, Advisor



**JORIS VERSTER**  
PhD,  
Scientific Advisory Board  
International Clinical Expert



**FRANCIS FARRAYE**  
MD, MSC,  
Scientific Advisory Board  
Physician + GI Thought Leader



**ANDREW SCHOLEY**  
PhD,  
Scientific Advisory Board  
Brain and Mental Health Expert



**GARY ZAMMIT**  
PhD,  
Scientific Advisory Board  
Expert Drug Developer

# WE'RE RAISING CAPITAL TO ADVANCE OUR ASSETS THROUGH PHASE 2 CLINICAL TRIALS & SECURE LICENSING DEALS

## \$11.5M RAISED TO DATE

### 2024 HIGHLIGHTS:

- Completed Phase 2 SJP-002C (URI/COVID) trial with Duke University
- Started Phase 2 Trial for SJP-001 (Overindulgence of Food & Drink) trial
- Completed 1 of 2 studies for SJP-001 (Opioid Withdrawal) with NIDA
- Completed FDA submission batches for SJP-002C and R&D batches for SJP-001
- Partnership w/ KVK for SJP-100 (Injectable)
- 3 patents filed, 6 patents granted, total patent granted 34, patents pending 26
- Completed Market Analysis & Valuation for SJP-002C & SJP-001

## SEEKING TO RAISE \$5M IN 2025

### 2025 USES OF CAPITAL:

- Phase 2 readout for SJP-002C (URI/COVID)
- Complete Phase 2 Trial for SJP-001
- Open INDs for SJP-002C and SJP-002
- Secure licensing agreement(s) for SJP-002C
- Secure licensing agreement(s) for SJP-001
- Complete 2 of 2 studies for SJP-005 with NIDA
- Complete Market Analysis & Valuation for SJP-001 (Obesity), SJP-002C (URI, Obesity, & MASLD), SJP-002 (Common Cold), and SJP-005 (Opioid Withdrawal)
- Complete GMP product and Pre-Clinical work for SJP-100 for Opioid Withdrawal and Liver Disease
- Initiate Partnership w/KVK for SJP-002 (Common Cold)
- Seeking Licensees, Investors, & Co-Development Partners

# sen-Jam

PHARMACEUTICAL

**IMPACTING THE LIVES  
OF BILLIONS BY  
CHANGING THE COURSE  
OF INFLAMMATION**

**JIM IVERSEN, CO-FOUNDER, CEO**  
201.400.8083  
[jiversen@sen-jam.com](mailto:jiversen@sen-jam.com)

**JACKIE IVERSEN, CO-FOUNDER, CCO**  
[jackie@sen-jam.com](mailto:jackie@sen-jam.com)

